ClinicalTrials.gg
TerminatedNCT00313014Updated Sep 3, 2012Results posted

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

A Phase 3 interventional study of Buprenorphine and Buprenorphine in Back Pain Lower Back Chronic, sponsored by Purdue Pharma LP. Terminated at 85 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-03.

Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated early due to administrative reasons unrelated to efficacy or safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies testing buprenorphine in Low Back Pain — none open to participants now, none under way, none of them phase 3. Buprenorphine · Low Back Pain.

Enrollment
3rd of 13
660 · median 302
Started
2004
with 1 other
Phase 3
10 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
4 of 13
Purdue Pharma LP

Among the 13 studies testing buprenorphine in Low Back Pain, this one is the 3rd largest by enrollment, is one of 2 that started in 2004, is one of 10 in phase 3, and was the 1st registered.

Low Back Pain

2,927 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

None of the 13 studies testing buprenorphine in Low Back Pain is open now. The open studies under Low Back Pain, anywhere →

About buprenorphine

Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing buprenorphine in Low Back Pain as a file.
02

Study summary

The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) 20 in comparison to the buprenorphine transdermal system (BTDS) 5 and oxycodone immediate-release in subjects with moderate to severe low back pain currently treated with oral opioids. The double-blind treatment intervention duration is 12 weeks during which time supplemental analgesic medication (acetaminophen, ibuprofen) will be provided to all subjects in addition to study drug.

Read the detailed description

Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

03

Conditions studied

  • Back Pain Lower Back Chronic

Browse trials for

Keywords

  • Low back pain
  • opioid
  • transdermal
  • Butrans
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • low back pain for 3 months or longer, confirmed by radiographic evidence.
  • receiving a stable dose of an opioid analgesic for low back pain.

Exclusion criteria

Exclusion Criteria:

  • taking more than 80 mg per day of oral morphine sulfate or equivalent within 30 days of enrollment.
  • requiring frequent analgesic therapy for chronic condition(s), in addition to low back pain.

Other protocol-specific exclusion/inclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
660 participants (actual)

Study arms

  • Active comparator
    BTDS 5

    Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.

    Drug: Buprenorphine

  • Experimental
    BTDS 20

    Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.

    Drug: Buprenorphine

  • Experimental
    Oxycodone Immediate-Release

    Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).

    Drug: Oxycodone Immediate-Release

Interventions

  • Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.

    Also known as: Butrans™

  • Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear

    Also known as: Butrans™

  • DrugOxycodone Immediate-Release

    Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).

06

What researchers measure

Primary outcomes

  1. Average Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.

    Subjects were evaluated during the double-blind phase for "average pain over the last 24 hours" prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)

    Time frame: Last 24 hours score at weeks 4, 8, 12 of the double-blind phase

Secondary outcomes

  1. Mean Daily Number of Supplemental Analgesic Tablets

    The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase

    Time frame: Double-blind phase (84 days)

  2. Oswestry Disability Index (ODI) Score (V 2.0)

    The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)

    Time frame: Weeks 4, 8, 12

  3. The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.

    The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath). Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.

    Time frame: Weeks 4, 8, 12 of the double-blind phase

07

Results

Posted Sep 29, 2010
Limitations and caveats
BUP3015 was terminated early due to administrative reasons unrelated to efficacy or safety.

Participant flow

The study began with first patient first visit (FPFV) on 25-Feb-2004 to last patient last visit (LPLV) on 23-Sep-2005, at 75 medical/research sites in the United States.

Participant flow — Overall Study
MilestoneDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Started221219220
Completed128146159
Not completed937361
Withdrew: Withdrawal by subject1175
Withdrew: Adverse event142916
Withdrew: Lost to follow-up7610
Withdrew: Administrative9614
Withdrew: Lack of efficacy522516

Outcome measures

PrimaryAverage Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.

Subjects were evaluated during the double-blind phase for "average pain over the last 24 hours" prior to the study visits. Pain scale is 11 points (0 = no pain to 10 = pain as bad as you can imagine)

Time frame:
Last 24 hours score at weeks 4, 8, 12 of the double-blind phase
Reported as:
Mean · units on a scale
Average Pain Over the Last 24 Hours Score at Weeks 4, 8, and 12.
units on a scaleDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Screening6.36 ± 0.0756.46 ± 0.0846.46 ± 0.079
Prerandomization2.84 ± 0.0752.91 ± 0.0752.74 ± 0.074
Week 43.79 ± 0.1493.40 ± 0.1283.14 ± 0.125
Week 83.83 ± 0.1623.35 ± 0.1403.24 ± 0.145
Week 124.02 ± 0.1793.35 ± 0.1393.26 ± 0.152
Statistical analysis
  • Double-blind BTDS 5 vs Double-blind BTDS 20 · Mixed Models Analysis · p = <.001 (P value was 2-sided and performed at the 5% error level.) · Mean difference (final values): -0.67 · 95% CI -0.99 to -0.35Repeated measures mixed linear model with treatment, time, and time by treatment interaction as fixed effects.
  • Double-blind BTDS 5 vs Double-blind Oxycodone Immediate-Release · Mixed Models Analysis · p = <.001 (P value was 2-sided and performed at the 5% error level.) · Mean difference (final values): -0.75 · 95% CI -1.07 to -0.44Repeated measures mixed linear model with treatment, time, and time by treatment interaction as fixed effect.
SecondaryMean Daily Number of Supplemental Analgesic Tablets

The mean daily number of tablets of supplemental analgesic medications used during the double-blind phase

Time frame:
Double-blind phase (84 days)
Reported as:
Mean · tablets
Mean Daily Number of Supplemental Analgesic Tablets
tabletsDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Mean Daily Number of Supplemental Analgesic Tablets3.8 ± 0.123.3 ± 0.133.5 ± .13
Statistical analysis
  • Double-blind BTDS 5 vs Double-blind BTDS 20 · ANCOVA · p = .006 (To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.) · Mean difference (final values): -0.5 · 95% CI -0.90 to -0.13The analysis was based on the number of subjects who took \> 1 tablet of supplemental analgesia.
  • Double-blind BTDS 5 vs Double-blind Oxycodone Immediate-Release · ANCOVA · p = .158 (To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.) · Mean difference (final values): -0.3 · 95% CI -0.70 to 0.09The analysis was based on the number of subjects who took \> 1 tablet of supplemental analgesia.
SecondaryOswestry Disability Index (ODI) Score (V 2.0)

The ODI (version 2) is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire that is usually completed in less than 5 minutes. The ODI consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0 = good to 5 = worse). (Note: A higher score represents greater disability.)

Time frame:
Weeks 4, 8, 12
Reported as:
Mean · units on a scale
Oswestry Disability Index (ODI) Score (V 2.0)
units on a scaleDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Week 434.80 ± 1.06633.04 ± 1.01930.79 ± 1.124
Week 835.69 ± 1.24534.27 ± 1.09431.64 ± 1.165
Week 1236.30 ± 1.39233.06 ± 1.23132.96 ± 1.243
Statistical analysis
  • Double-blind BTDS 5 vs Double-blind BTDS 20 · Mixed Models Analysis · p = .065 (To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.) · Mean difference (final values): -1.72 · 95% CI -3.55 to 0.11
  • Double-blind BTDS 5 vs Double-blind Oxycodone Immediate-Release · Mixed Models Analysis · p = .031 (To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.) · Mean difference (final values): -1.99 · 95% CI -3.79 to -0.18
SecondaryThe Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.

The MOS-Sleep Scale consists of 12 individual items: (4 sleep disturbance, 2 sleep adequacy, 1 quantity/ optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath). Question 1 is scored on a scale of 1 to 5 and Questions 3 to 12 are scored on a scale of 1 to 6. The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7 and 8, and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.

Time frame:
Weeks 4, 8, 12 of the double-blind phase
Reported as:
Mean · units on a scale
The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4, 8, and 12.
units on a scaleDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-Release
Week 440.67 ± 2.02534.65 ± 1.60738.10 ± 1.788
Week 842.28 ± 2.26435.69 ± 1.72139.17 ± 1.924
Week 1240.85 ± 2.37633.65 ± 1.94141.60 ± 2.205
Statistical analysis
  • Double-blind BTDS 5 vs Double-blind BTDS 20 · Mixed Models Analysis · p = <.001 (To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.) · Mean difference (final values): -6.23 · 95% CI -9.64 to -2.82Mixed linear model: treatment, time as fixed effects, screening, prerandomization sleep disturbance subscale as covariates; subject as a random effect
  • Double-blind BTDS 5 vs Double-blind Oxycodone Immediate-Release · Mixed Models Analysis · p = .121 (To address the issue of multiplicity and control the family-wise error rate, a gate-keeping strategy and a stepwise approach (Holm's methodology) were used to evaluate the statistical significance of the secondary efficacy analyses.) · Mean difference (final values): -2.65 · 95% CI -6.01 to 0.70

Adverse events

Collected over Adverse events occurring after the signing of the informed consent up to end of study and 7 days after, discontinuation, or serious AEs occurring up to 30 days following the last study visit were followed until the AE or sequelae resolved or stabilized.. Non-serious events are listed at a 4.50% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind BTDS 5—6/221 (2.7%)54/221 (24.4%)
Double-blind BTDS 20—7/219 (3.2%)118/219 (53.9%)
Double-blind Oxycodone Immediate-Release—9/220 (4.1%)93/220 (42.3%)
Open-label Run-in Period, BTDS 10/20—10/1,160 (0.9%)389/1,160 (33.5%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-ReleaseOpen-label Run-in Period, BTDS 10/20
PancreatitisGastrointestinal disorders2/2210/2190/2200/1160
HematemesisGastrointestinal disorders0/2211/2190/2200/1160
Intractable vomitingGastrointestinal disorders0/2211/2190/2200/1160
Chest pressureGeneral disorders0/2211/2190/2200/1160
Acute cholecystitisHepatobiliary disorders0/2211/2190/2200/1160
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2211/2190/2200/1160
Abdominal aortic aneurysmVascular disorders0/2211/2190/2200/1160
NauseaGastrointestinal disorders0/2211/2190/2200/1160
VomitingGastrointestinal disorders0/2211/2190/2200/1160
Increased total bilirubinInvestigations0/2211/2190/2200/1160
Most frequent other events
Showing 10 of 12
Most frequent other events
EventDouble-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-ReleaseOpen-label Run-in Period, BTDS 10/20
NauseaGastrointestinal disorders18/22127/21918/220174/1160
Application site pruritusGeneral disorders12/22129/21920/220102/1160
HeadacheNervous system disorders12/22125/21921/220124/1160
Application site erythemaGeneral disorders10/22122/21919/22038/1160
Application site rashGeneral disorders17/22120/21913/22038/1160
ConstipationGastrointestinal disorders7/22114/21914/22046/1160
SomnolenceNervous system disorders4/22110/21911/22067/1160
DizzinessNervous system disorders5/22110/2198/22062/1160
Vomiting NOSGastrointestinal disorders5/22111/2199/22060/1160
ArthralgiaMusculoskeletal and connective tissue disorders5/22110/2194/2208/1160

Baseline characteristics

Age Continuous
Age Continuous(years)Double-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-ReleaseTotal
Mean50.2 ± 12.8850.4 ± 11.9349.5 ± 12.3750.0 ± 12.39
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind BTDS 5Double-blind BTDS 20Double-blind Oxycodone Immediate-ReleaseTotal
Female101113100314
Male120106120346
08

Study locations

85 sites
  • Birmingham Pain Center
    Birmingham, Alabama 35244, United States
  • Arthritis Clinical Intervention Program
    Birmingham, Alabama 35249, United States
  • Winston Physician Services, LLC
    Haleyville, Alabama 35565, United States
  • Arizona Research Center, Inc.
    Phoenix, Arizona 85023, United States
  • Radiant Research
    Phoenix, Arizona 85029, United States
  • Advanced Clinical Therapeutics
    Tuscon, Arizona 85712, United States
  • Hot Springs Pain Clinic
    Hot Springs, Arkansas 71913, United States
  • NuLife Clinical Research, Inc.
    Anaheim, California 92805, United States
  • Lovelace Scientific Resources, Inc.
    Beverly Hills, California 90211, United States
  • Northern California Research Corp
    Carmichael, California 95608, United States
  • International Clinical Research Network
    Chula Vista, California 91911, United States
  • Shreenath Clinical Service
    Fountain Valley, California 92708, United States
  • U of Calif at Davis, Med Ctr, Pain Management Center
    Sacramento, California 95817, United States
  • Accelovance
    San Diego, California 92108, United States
  • Southern Colorado Clinic
    Pueblo, Colorado 81008, United States
  • Chiefland Medical Center
    Chiefland, Florida 32626, United States
  • University Clinical Research, Inc.
    Deland, Florida 32720, United States
  • Drug Study Institute
    Jupiter, Florida 33458, United States
  • Innovative Research of West Florida, Inc.
    Largo, Florida 33770, United States
  • Renstar Medical
    Ocala, Florida 34471, United States
  • Peninsula Research Inc.
    Ormond Beach, Florida 32174, United States
  • The Arthritis Center
    Palm Harbor, Florida 34684, United States
  • University Clinical Research, Inc.
    Pembroke Pines, Florida 33024, United States
  • Gold Coast Research, LLC
    Plantation, Florida 33324, United States
  • Coastal Medical Research
    Port Orange, Florida 32168, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Georgia Medical Research Institute
    Marietta, Georgia 30060, United States
  • Atlanta Knee & Shoulder Clinic
    Stockbridge, Georgia 30281, United States
  • Pain Care Boise
    Boise, Idaho 83702, United States
  • Idaho Arthritis and Osteoporosis Center
    Meridian, Idaho 83742, United States
  • Pain and Rehabilitation Clinic of Chicago
    Chicago, Illinois 60610, United States
  • GFI Research Center
    Evansville, Indiana 47714, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Medical Associates Clinics
    Dubuque, Iowa 52002, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66211, United States
  • CTT, Inc.
    Prairie Village, Kansas 66206, United States
  • Commonwealth Biomedical Research, LLC
    Madisonville, Kentucky 42431, United States
  • New Orleans Clinical Trial Management Inc.
    Metairie, Louisiana 70006, United States
  • Louisiana Research Associates, Inc.
    New Orleans, Louisiana 70114, United States
  • Best Clinical Trials, LLC
    New Orleans, Louisiana 70115, United States
  • Research Center of Louisiana
    New Orleans, Louisiana 70115, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Future Care Studies
    Springfield, Massachusetts 11070, United States
  • Rheumatology PC
    Kalamazoo, Michigan 49009, United States
  • Lake Michigan Clinical Research & Consulting, Inc.
    Saint Joseph, Michigan 49085, United States
  • Medex Healthcare Research, Inc.
    St Louis, Missouri 63108, United States
  • HealthCare Research
    St Louis, Missouri 63141, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Lovelace Scientific Resources
    Henderson, Nevada 89014, United States
  • Pivotal Research Centers
    North Las Vegas, Nevada 89030, United States
  • Research Across America
    New York, New York 10022, United States
  • Pain and Orthopedic Neurology , Charlotte Spine Center,
    Charlotte, North Carolina 28207, United States
  • Metrolina Medical Research
    Charlotte, North Carolina 28209, United States
  • Triangle Orthopaedic Associates
    Durham, North Carolina 27704, United States
  • Pharmquest
    Greensboro, North Carolina 27401, United States
  • MedArk Clinical Research
    Morgantown, North Carolina 28655, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Center for Clinical Research
    Winston Salem, North Carolina 27103, United States
  • Odyssey Research
    Bismark, North Dakota 58502, United States
  • COR Clinical Research, LLC
    Oklahoma City, Oklahoma 73103, United States
  • Associated Medical Services
    Oklahoma City, Oklahoma 73112, United States
  • Keystone Clinical Research
    Altoona, Pennsylvania 16602, United States
  • Valley Pain Specialists
    Bethlehem, Pennsylvania 18016, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Central Pennsylvania Clinical Research
    Mechanicsburg, Pennsylvania 17055, United States
  • BioMedical Research Associates
    Shippensburg, Pennsylvania 17257, United States
  • University Orthopedics Center
    State College, Pennsylvania 16801, United States
  • New England Center Clinical Research
    Cranston, Rhode Island 29200, United States
  • Omega Medical Research
    Warwick, Rhode Island 28860, United States
  • Arthritis & Osteoporosis Center
    Orangeburg, South Carolina 29118, United States
  • Brown Clinic
    Watertown, South Dakota 57201, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Tri Cities Medical Research
    Bristol, Tennessee 37620, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Galenos Research
    Dallas, Texas 75251, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • Team Research of Central Texas
    Harker Heights, Texas 76548, United States
  • KRK Medical Research
    Richardson, Texas 75080, United States
  • Benchmark Research
    San Angelo, Texas 76904, United States
  • Unlimited Research
    San Antonio, Texas 78233, United States
  • Texas Medical Research Associates
    San Antonio, Texas 78238, United States
  • Clinical Trial Network Oaks Medical Center
    Spring, Texas 77386, United States
  • N. Texas Neuro Research
    Wichita Falls, Texas 76301, United States
  • Lifetree Clinical Research
    Salt Lake City, Utah 84106, United States
  • Dean Medical Center
    Oregon, Wisconsin 53575, United States
09

References and documents

Publications

  • Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011 Nov;12(11):1163-73. doi: 10.1016/j.jpain.2011.06.003. Epub 2011 Jul 31. PubMed 21807566 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2006
First posted
Apr 11, 2006
Start
Feb 2004
Primary completionActual
Sep 2005
CompletionActual
Sep 2005
Results first posted
Sep 29, 2010
Last update
Sep 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00313014
Lead sponsor
Purdue Pharma LP
Responsible party
Sponsor
First posted
Apr 11, 2006
Start date
Feb 2004
Primary completion
Sep 2005
Completion
Sep 2005
Results posted
Sep 29, 2010
Last update
Sep 3, 2012

Study contacts

Martin Hale, MD
principal investigator · Gold Coast Research LLC, Weston, FL, USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buprenorphine

Start the discussion